Intellia Therapeutics Announces Third Quarter 2019 Financial Results On track to submit in mid-2020 an investigational new drug application for NTLA-2001 for the treatment of transthyretin amyloidosis Expects to nominate

Intellia Therapeutics Announces Third Quarter 2019 Financial Results

CAMBRIDGE, Mass., October 31, 2019 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), reported operational highlights and financial

results for the third quarter ended September 30, 2019.

In 2019, we continued to leverage the breadth of our genome editing platform to

advance our in vivo and engineered cell therapy programs. We have demonstrated that we can knock out a disease-causing gene as well as introduce a functional gene to restore normal protein production. Now, we have achieved consecutive editing

in vivo by combining both these edit types, further highlighting the versatility of our modular platform, said Intellia President and Chief Executive Officer, John Leonard, M.D. Our full-spectrum strategy and platform capabilities

are enabling Intellia s development of a robust pipeline to address a range of severe diseases. We look forward to the planned nomination of our first engineered cell therapy development candidate for acute myeloid leukemia by year-end and the submission of our first IND application for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020.

Third Quarter 2019 and More Recent Operational Highlights

The Company has set forth the following for pipeline progression:

The Company will participate in the

following investor events:

Third Quarter 2019 Financial Results

Intellia expects that its cash, cash equivalents and marketable securities as of September 30, 2019, as well as technology access and funding from

Novartis and Regeneron, will enable Intellia to fund its anticipated operating expenses and capital expenditure requirements into the second half of 2021. This expectation excludes any potential milestone payments or extension fees that could be

earned and distributed under the collaboration agreements with Novartis and Regeneron or any strategic use of capital not currently in the Company s base-case planning assumptions.

Conference Call to Discuss Third Quarter 2019 Earnings

The Company will discuss these results on a conference call today, October 31, 2019, at 8 a.m. ET.

A replay of the call will be available through the Events and Presentations page of the Investor Relations section on Intellia s website, beginning on

October 31, 2019 at 12 p.m. ET.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using the CRISPR/Cas9 system. Intellia believes the

CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or

can replace patients diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic

Forward-Looking Statements

This press release contains

forward-looking statements of Intellia Therapeutics, Inc. ( Intellia or the Company ) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not

limited to, express or implied statements regarding Intellia s beliefs and expectations regarding its planned submission of an investigational new drug ( IND ) application for NTLA-2001 for the treatment of transthyretin amyloidosis

( ATTR ) in mid-2020; its plans to nominate a first T cell receptor ( TCR )-directed engineered cell therapy development candidate for its acute myeloid leukemia ( AML ) program

by the end of 2019; its plans to advance and complete preclinical studies, including non-human primate studies for its ATTR program, AML program and other in vivo and ex vivo programs; develop

our proprietary LNP-AAV hybrid delivery system to advance our complex genome editing capabilities, such as gene insertion; its presententation of additional data at upcoming scientific conferences, and other

preclinical data by the end of 2019; the advancement and expansion of its CRISPR/Cas9 technology to develop human therapeutic products, as well as maintain and expand its related intellectual property portfolio; the ability to demonstrate its

platform s modularity and replicate or apply results achieved in preclinical studies, including those in its ATTR and AML programs, in any future studies, including human clinical trials; its ability to develop other in vivo

or ex vivo cell therapeutics of all types, and those targeting WT1 in AML in particular, using

CRISPR/Cas9 technology; the ability to continue its growth and realize the anticipated contribution of the members of its board of directors and executives to its operations and progress; the

impact of its collaborations on its development programs, including but not limited to its collaborations with Regeneron Pharmaceuticals, Inc. and Novartis Institutes for BioMedical Research; statements regarding the timing of regulatory filings

regarding its development programs; its use of capital, including ATM receivables, expenses, future accumulated deficit and other financial results during the third quarter of 2019; and the ability to fund operations into the second half of

Any forward-looking statements in this press release are based on management s current expectations and beliefs of future events, and are

subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to:

risks related to Intellia s ability to protect and maintain our intellectual property position, including through our arbitration proceedings against Caribou; risks related to Intellia s relationship with third parties, including our

licensors; risks related to the ability of our licensors to protect and maintain their intellectual property position; uncertainties related to the initiation and conduct of studies and other development requirements for our product candidates; the

risk that any one or more of Intellia s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with

future studies; the risk that Novartis will not continue to pursue programs it has selected through its collaboration with Intellia; and the risk that Intellia s collaborations with Novartis or Regeneron or its other ex vivo

collaborations will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia s actual results to differ from those contained in the

forward-looking statements, see the section entitled Risk Factors in Intellia s most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other

important factors in Intellia s other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless

INTELLIA THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(Amounts in thousands, except per share data)

INTELLIA THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(Amounts in thousands)

Jennifer Mound Smoter

Senior Vice President

External Affairs & Communications